Febit minimal genome technology receives EU patent
Minimal-genome synthesis technology
Febit has announced the receipt of an EU patent, EP 1 728 860B1, for its technology to synthesise minimal genomes.
The patent protects Febit's technology for combining genes to construct a minimal functional genome or parts of it.
The EU patent complements earlier patents on the synthesis of oligonucleotides for gene assembling.
Febit's portfolio also contains technologies for the exploration of the genome.
Hybselect, for example, is a technology for the enrichment of interesting genes for targeted resequencing.
Febit's miRNA profiling enables the discovery and evaluation of new biomarker signatures for various diseases.
In addition to bioanalytics, the company's intellectual property portfolio predominantly covers the production of synthetic genes on biochips.
Study results that illustrate the high potential of microRNAs (miRNAs) as biomarkers for a range of diseases will be presented during the 42nd European Human Genetics Conference in Sweden.
Febit has announced that it now offers whole-genome sequencing services in Europe for a range of species.
Febit has announced that an updated version of the company's miRBase 14 Geniom Biochip with 58 additional new sequences is now available for cancer research.
The Children's Hospital Boston has selected Febit's Hybselect technology to enable genetics researchers to conduct the highly economic targeted enrichment of genes of interest for resequencing.
3 December 2009 - Febit's Hybselect has been recognised as one of the winners of the Top 10 Innovations of 2009 by The Scientist magazine.